What Are Wall Street Analysts' Target Price for Edwards Lifesciences Stock?

Company Overview - Edwards Lifesciences Corporation (EW) is valued at a market cap of $45.7 billion and specializes in products and technologies for advanced cardiovascular diseases, emphasizing a patient-centric approach and collaboration with physicians [1] Market Performance - Over the past 52 weeks, EW has underperformed the broader market, gaining 10.9% compared to the S&P 500 Index's 14% increase. Year-to-date, EW's stock is down 7.7%, while the S&P 500 has returned 1.3% [2] - Despite this, EW has outperformed the iShares U.S. Medical Devices ETF (IHI), which declined 8.9% over the past 52 weeks and 6.1% year-to-date [3] Financial Results - On October 30, EW reported Q3 results, with net sales of $1.6 billion, reflecting a 14.7% year-over-year increase. The adjusted EPS remained stable at $0.67, exceeding consensus expectations by 13.6% [6] Earnings Expectations - For the current fiscal year ending in December, analysts project EW's EPS to grow 6.6% year-over-year to $2.59. The company has a strong earnings surprise history, exceeding consensus estimates in the last four quarters [7] Analyst Ratings - Among 31 analysts covering EW, the consensus rating is a "Moderate Buy," consisting of 18 "Strong Buy," 2 "Moderate Buy," and 11 "Hold" ratings [7] - The configuration has become more bullish, with 17 analysts suggesting a "Strong Buy" rating. UBS Group AG analyst Danielle Antalffy maintained a "Neutral" rating but lowered the price target to $94, indicating a 19.4% potential upside. The mean price target of $96.71 suggests a 22.9% premium, while the highest price target of $110 indicates a 39.8% potential upside [8]